Table 1.
Baseline Characteristics of Postmenopausal Women with Osteoporosis Younger than 75 and Aged 75 and Older in Both Treatment Groups
| Characteristic | <75
|
≥75
|
||
|---|---|---|---|---|
| Placebo (n =2,736) | ZOL (n =2,731) | Placebo (n =1,927) | ZOL (n =1,961) | |
| Age, mean ± SD | 69.1 ± 3.7 | 69.2 ± 3.7 | 79.6 ± 3.7 | 79.3 ± 3.7 |
|
| ||||
| Body mass index, kg/m2, mean ± SD | 25.4 ± 4.4 | 25.1 ± 4.4 | 25.2 ± 4.2 | 25.1 ± 4.3 |
|
| ||||
| Femoral neck bone mineral density, g/cm2, mean ± SD | 0.6 ± 0.1 | 0.6 ± 0.1 | 0.5 ± 0.1 | 0.5 ± 0.1 |
|
| ||||
| Femoral neck T score, n (%) | ||||
|
| ||||
| ≤−2.5 | 1,715 (62.7) | 1,806 (66.1) | 1,361 (70.6) | 1,362 (69.5) |
|
| ||||
| >−2.5 | 977 (35.7) | 887 (32.5) | 495 (25.7) | 510 (26) |
|
| ||||
| Prevalent vertebral fracture, n (%)* | ||||
|
| ||||
| 0 | 946 (39.3) | 971 (40.8) | 437 (30.1) | 486 (32.5) |
|
| ||||
| 1 | 666 (27.6) | 657 (27.6) | 410 (28.2) | 436 (29.1) |
|
| ||||
| ≥2 | 796 (33.1) | 749 (31.5) | 605 (41.7) | 574 (38.3) |
|
| ||||
| Serum creatinine, mg/dL, mean ± SD | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.2 |
|
| ||||
| Calculated creatinine clearance, mL/min, mean ± SD | 70.8 ± 19.2 | 70.0 ± 19.0 | 55.8 ± 15.8 | 55.6 ± 15.0 |
|
| ||||
| Calculated creatinine clearance, mL/min, n (%) | ||||
|
| ||||
| <30.0 | 0 (0.0) | 0 (0.0) | 4 (0.2) | 1 (0.1) |
|
| ||||
| 30.0–34.9 | 13 (0.5) | 17 (0.6) | 120 (6.2) | 90 (4.6) |
|
| ||||
| 35.0–39.9 | 38 (1.4) | 42 (1.5) | 156 (8.1) | 175 (8.9) |
|
| ||||
| 40.0–49.9 | 250 (9.1) | 269 (9.8) | 501 (26.0) | 505 (25.8) |
|
| ||||
| 50.0–59.9 | 516 (18.9) | 535 (19.6) | 476 (24.7) | 515 (26.3) |
|
| ||||
| ≥60.0 | 1,919 (70.1) | 1,867 (68.4) | 666 (34.6) | 671 (34.2) |
|
| ||||
| Missing | 0 (0.0) | 1 (0.1) | 4 (0.2) | 4 (0.2) |
*
Data from Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly Pivotal Fracture Trial only.
ZOL =once-yearly zoledronic acid 5 mg; SD =standard deviation.